PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Clinical trials for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE explained in plain language.
Never miss a new study
Get alerted when new PULMONARY DISEASE, CHRONIC OBSTRUCTIVE trials appear
Sign up with your email to follow new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cut COPD attacks in patients with specific inflammation
Disease control Recruiting nowThis study tests whether adding depemokimab early to standard COPD treatment can reduce moderate to severe flare-ups in people with moderate to severe COPD who have type 2 inflammation. About 1,200 participants will receive either depemokimab or a placebo as an add-on therapy. Th…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug aims to cut COPD Flare-Ups in patients with type 2 inflammation
Disease control Recruiting nowThis study tests an experimental drug called depemokimab in adults aged 40 to 80 with moderate to severe COPD and type 2 inflammation. The goal is to see if adding this medicine to standard care can reduce the number of serious flare-ups that require steroids, antibiotics, or hos…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug aims to cut dangerous COPD attacks in half
Disease control Recruiting nowThis study tests an experimental drug called depemokimab for people with moderate to severe COPD who also have type 2 inflammation. The goal is to see if adding this medicine to standard treatment can reduce the number of serious flare-ups that require steroids, antibiotics, or h…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Stem cells may fix COPD lungs – early study launched
Knowledge-focused Recruiting nowThis study tests whether induced pluripotent stem cells (iPS cells) can repair damaged lung tissue from people with COPD. Researchers will take small lung samples from 50 participants (COPD patients, smokers without COPD, and non-smokers) during a routine bronchoscopy. In the lab…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Breath test may replace needles for COPD patients
Knowledge-focused Recruiting nowThis study looks at whether a non-invasive breath measurement (EtCO2) can help doctors quickly tell how serious a COPD attack is. Researchers will monitor 240 adults in the emergency room to see if EtCO2 levels can predict the need for breathing support. If successful, this could…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can aspirin ease COPD symptoms? new study seeks answers
Knowledge-focused Recruiting nowThis study is testing different doses of aspirin to see which one best reduces inflammation in people with COPD. The goal is to find the right dose that could improve breathing and reduce flare-ups. The study involves 48 former smokers with COPD and will measure blood and urine m…
Matched conditions: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE
Phase: PHASE3 • Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC